TY - JOUR
T1 - Increased risk of myocardial infarction with dabigatran
T2 - Fact or fiction?
AU - Giglio, Ada F.
AU - Basile, Eloisa
AU - Santangeli, Pasquale
AU - Di Biase, Luigi
AU - Trotta, Francesco
AU - Natale, Andrea
PY - 2014
Y1 - 2014
N2 - Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In some of the clinical trials evaluating the efficacy and safety of dabigatran in different clinical settings [i.e., prevention of venous thromboembolism (VTE) after orthopedic surgery, secondary prevention of VTE, and acute coronary syndromes (ACS)], a trend toward an increase in acute coronary events among patients receiving dabigatran has been reported, thus raising concerns of a possible relationship between dabigatran and myocardial infarction, especially in high-risk patients. However, as shown in our article, current evidence is inconclusive on this topic; more data are needed to detail this hypothetical association, and other considerations, such as the well-known protective effect of warfarin against ACS, should be taken into account as a possible explanation.
AB - Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In some of the clinical trials evaluating the efficacy and safety of dabigatran in different clinical settings [i.e., prevention of venous thromboembolism (VTE) after orthopedic surgery, secondary prevention of VTE, and acute coronary syndromes (ACS)], a trend toward an increase in acute coronary events among patients receiving dabigatran has been reported, thus raising concerns of a possible relationship between dabigatran and myocardial infarction, especially in high-risk patients. However, as shown in our article, current evidence is inconclusive on this topic; more data are needed to detail this hypothetical association, and other considerations, such as the well-known protective effect of warfarin against ACS, should be taken into account as a possible explanation.
KW - atrial fibrillation
KW - dabigatran
KW - myocardial infarction
UR - http://www.scopus.com/inward/record.url?scp=84894091265&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894091265&partnerID=8YFLogxK
U2 - 10.2459/JCM.0b013e328364beb8
DO - 10.2459/JCM.0b013e328364beb8
M3 - Review article
C2 - 24492353
AN - SCOPUS:84894091265
SN - 1558-2027
VL - 15
SP - 19
EP - 26
JO - Journal of Cardiovascular Medicine
JF - Journal of Cardiovascular Medicine
IS - 1
ER -